Licensing discussions19 May 2020 19:53
Pharma Plc (AIM: N4P), a specialist pharmaceutical company, has announced results fromthe company’s latest research study into its novel silica nanoparticle for cancer treatments and vaccines, Nuvec®. The work, which repeated and expanded on a previouspDNA OVA study, has demonstrated that Nuvec® is capable of working in vivo when using multiple injections at specific doses.
Together with previously acquired data, these results also confirm that Nuvec®, under the appropriate conditions, can promote transfection using both DNA and RNA. N4 Pharma will now focus its final pre-clinical development programmes on optimising the Nuvec® loading process in order to increase the consistency of the in vivo performance. Once successful, this will allow the company to move from exploratory collaborations to engage in full licensing discussions.